It is privately held and was founded in 2005 by Drs. Tobias Allander, Mats A A Persson, and Mr. Staffan Söderström. The company is focusing its efforts to develop human monoclonal antibodies for treatment or protection against hepatitis C, a liver disease caused by the hepatitis C virus (HCV) and estimated to affect 170 million people worldwide. Human antibodies against the HCV surface proteins will be used; they have recently shown very potent and broad antiviral effects against HCV of all known subfamilies.
- Bli medlem
- Om SwedenBIO